SU1165223A3 - Способ получени эргоалкалоидов - Google Patents

Способ получени эргоалкалоидов Download PDF

Info

Publication number: SU1165223A3
Authority: SU; USSR - Soviet Union
Prior art keywords: ergoalkaloids; methanesulfonate; mixture; fact; flask
Prior art date: 1975-10-17

Application number

SU762412401A

Other languages

English (en)

Russian (ru)

Inventor

Эрхардт Лотар

Хартманн Фолькер

Патт Людвиг

Отто Карл-Хайнц

Original Assignee

Сандос Аг (Фирма)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-10-17

Filing date

1976-10-15

Publication date

1985-06-30

1976-10-15 Application filed by Сандос Аг (Фирма) filed Critical Сандос Аг (Фирма)

1985-06-30 Application granted granted Critical

1985-06-30 Publication of SU1165223A3 publication Critical patent/SU1165223A3/ru

Links

238000000034 method Methods 0.000 title claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 7
ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 claims description 5
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical class C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 claims description 3
229960002032 dihydroergocryptine Drugs 0.000 claims description 3
238000004090 dissolution Methods 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
239000003960 organic solvent Substances 0.000 claims 2
239000002202 Polyethylene glycol Substances 0.000 claims 1
LIMAOLZSWRJOMG-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C(C)C)C1=CC=CC=C1 LIMAOLZSWRJOMG-HJPBWRTMSA-N 0.000 claims 1
229960004318 dihydroergocristine Drugs 0.000 claims 1
238000010438 heat treatment Methods 0.000 claims 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
229920001223 polyethylene glycol Polymers 0.000 claims 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
239000002904 solvent Substances 0.000 claims 1
229920002554 vinyl polymer Polymers 0.000 claims 1
229920000036 polyvinylpyrrolidone Polymers 0.000 abstract description 6
239000001267 polyvinylpyrrolidone Substances 0.000 abstract description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract description 6
238000002360 preparation method Methods 0.000 abstract description 5
239000011343 solid material Substances 0.000 abstract 2
229930015720 peptide alkaloid Natural products 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000001035 drying Methods 0.000 description 4
235000019441 ethanol Nutrition 0.000 description 4
239000000654 additive Substances 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 1
UOOWRCRLTSXSAV-GSZJWLEYSA-N dihydroergocornine mesylate Chemical compound CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1 UOOWRCRLTSXSAV-GSZJWLEYSA-N 0.000 description 1
SPXACGZWWVIDGR-SPZWACKZSA-N dihydroergocristine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 SPXACGZWWVIDGR-SPZWACKZSA-N 0.000 description 1
HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
229960004704 dihydroergotamine Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
-1 polyethylene Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SU762412401A 1975-10-17 1976-10-15 Способ получени эргоалкалоидов SU1165223A3 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE2546577A DE2546577B2 (de)	1975-10-17	1975-10-17	Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden

Publications (1)

Publication Number	Publication Date
SU1165223A3 true SU1165223A3 (ru)	1985-06-30

Family

ID=5959411

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SU762412401A SU1165223A3 (ru)	1975-10-17	1976-10-15	Способ получени эргоалкалоидов

Country Status (28)

Country	Link
JP (1)	JPS5854122B2 (cs)
AT (1)	AT362510B (cs)
AU (1)	AU508628B2 (cs)
BE (1)	BE847368A (cs)
CA (1)	CA1079641A (cs)
CH (1)	CH643737A5 (cs)
CS (1)	CS199647B2 (cs)
DE (1)	DE2546577B2 (cs)
DK (1)	DK146194C (cs)
ES (1)	ES452420A1 (cs)
FI (1)	FI762875A7 (cs)
FR (1)	FR2327764A1 (cs)
GB (1)	GB1560406A (cs)
GR (1)	GR61268B (cs)
HK (1)	HK3183A (cs)
HU (1)	HU172533B (cs)
IE (1)	IE43778B1 (cs)
IL (1)	IL50686A (cs)
MY (1)	MY8400063A (cs)
NL (1)	NL184558C (cs)
NO (1)	NO144468C (cs)
NZ (1)	NZ182341A (cs)
PH (1)	PH14513A (cs)
PT (1)	PT65719B (cs)
SE (1)	SE430379B (cs)
SG (1)	SG63082G (cs)
SU (1)	SU1165223A3 (cs)
ZA (1)	ZA766166B (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1572226A (en) *	1977-11-03	1980-07-30	Hoechst Uk Ltd	Pharmaceutical preparations in solid unit dosage form
DK154607C (da) *	1978-12-21	1989-06-05	Sandoz Ag	Fremgangsmaade til fremstilling af en laegemiddelform til oral administration af ergotalkaloider
US4411882A (en)	1978-12-21	1983-10-25	Sandoz Ltd.	Galenical compositions
FR2454804B1 (fr) *	1979-04-26	1986-11-21	Sanofi Sa	Medicament a base de dihydroergotoxine et son procede de preparation
US4366145A (en) *	1981-06-24	1982-12-28	Sandoz, Inc.	Soft gelatin capsule with a liquid ergot alkaloid center fill solution and method of preparation
US4898729A (en) *	1983-12-09	1990-02-06	Euroceltique, S.A.	Treatment of hypertension, compounds and compositions for antihypertension and diuresis
HU198844B (en) *	1984-06-14	1989-12-28	Sandoz Ag	Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
DE3868077D1 (de) *	1987-01-14	1992-03-12	Ciba Geigy Ag	Therapeutisches system fuer schwerloesliche wirkstoffe.
FR2610827B1 (fr) *	1987-02-18	1991-09-13	Pf Medicament	Comprime de dihydroergotamine (d.h.e.) du type a matrice hydrophile et son procede de fabrication
US5064656A (en) *	1989-11-14	1991-11-12	Dr. Gergely & Co.	Uncoated pharmaceutical reaction tablet
DE4401646A1 (de) *	1994-01-21	1995-07-27	Krewel Werke Gmbh	Optimal freisetzende Kava-Extrakte
US6524832B1 (en)	1994-02-04	2003-02-25	Arch Development Corporation	DNA damaging agents in combination with tyrosine kinase inhibitors
NZ504834A (en) *	1997-12-22	2001-12-21	Schering Corp	Tricyclic amide molecular dispersion composition with enhanced bioavailability
US6632455B2 (en)	1997-12-22	2003-10-14	Schering Corporation	Molecular dispersion composition with enhanced bioavailability
US6316462B1 (en)	1999-04-09	2001-11-13	Schering Corporation	Methods of inducing cancer cell death and tumor regression
RU2256454C2 (ru) *	1999-12-03	2005-07-20	Полишем С.А.	Способы получения фармацевтических композиций алкалоидов спорыньи с пролонгированным действием, характеризующихся улучшенной биодоступностью, и содержащие указанные алкалоиды композиции
US7771746B2 (en)	1999-12-03	2010-08-10	Polichem Sa	Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
US7135436B2 (en)	2003-05-05	2006-11-14	J.F. Daley International, Ltd.	Solid algicide, preparation and usage in recirculating water
US20060141038A1 (en) *	2003-06-27	2006-06-29	Bioprogress S. P. A.	Composite product obtainable by cogrinding of a active principle with a copolymer n-vinyl-2 pyrrolidone/vinyl-acetate
CA2987867C (en)	2015-06-09	2023-06-27	Capsugel Belgium Nv	Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
KR102882996B1 (ko) *	2025-04-07	2025-11-07	(주)휴마스	액체크로마토그래피와 막전도도 측정모듈 및 개량된 uv산화반응기를 이용하는 분획된 수중 탄소 및 질소 측정장치 및 이를 이용한 측정방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1175430A (en) *	1966-04-07	1969-12-23	Sandoz Ltd	Pharmaceutical Compositions containing Ergot Alkaloids

1975
- 1975-10-17 DE DE2546577A patent/DE2546577B2/de not_active Withdrawn
1976
- 1976-10-01 CH CH1244876A patent/CH643737A5/de not_active IP Right Cessation
- 1976-10-08 SE SE7611189A patent/SE430379B/xx not_active IP Right Cessation
- 1976-10-08 DK DK454176A patent/DK146194C/da not_active IP Right Cessation
- 1976-10-08 NO NO763446A patent/NO144468C/no unknown
- 1976-10-08 FI FI762875A patent/FI762875A7/fi not_active Application Discontinuation
- 1976-10-13 NL NLAANVRAGE7611295,A patent/NL184558C/xx not_active IP Right Cessation
- 1976-10-14 CA CA263,423A patent/CA1079641A/en not_active Expired
- 1976-10-14 PH PH19008A patent/PH14513A/en unknown
- 1976-10-14 FR FR7630866A patent/FR2327764A1/fr active Granted
- 1976-10-15 NZ NZ182341A patent/NZ182341A/xx unknown
- 1976-10-15 AT AT767976A patent/AT362510B/de not_active IP Right Cessation
- 1976-10-15 ZA ZA00766166A patent/ZA766166B/xx unknown
- 1976-10-15 GB GB42907/76A patent/GB1560406A/en not_active Expired
- 1976-10-15 BE BE171578A patent/BE847368A/xx not_active IP Right Cessation
- 1976-10-15 PT PT65719A patent/PT65719B/pt unknown
- 1976-10-15 AU AU18754/76A patent/AU508628B2/en not_active Expired
- 1976-10-15 IE IE2282/76A patent/IE43778B1/en not_active IP Right Cessation
- 1976-10-15 ES ES452420A patent/ES452420A1/es not_active Expired
- 1976-10-15 IL IL50686A patent/IL50686A/xx unknown
- 1976-10-15 HU HU76SA00002985A patent/HU172533B/hu not_active IP Right Cessation
- 1976-10-15 CS CS766685A patent/CS199647B2/cs unknown
- 1976-10-15 SU SU762412401A patent/SU1165223A3/ru active
- 1976-10-16 JP JP51123463A patent/JPS5854122B2/ja not_active Expired
- 1976-10-16 GR GR51952A patent/GR61268B/el unknown
1982
- 1982-12-23 SG SG630/82A patent/SG63082G/en unknown
1983
- 1983-01-20 HK HK31/83A patent/HK3183A/xx unknown
1984
- 1984-12-30 MY MY63/84A patent/MY8400063A/xx unknown

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Патент US 3146169, кл. 424-15, 1962. *

Also Published As

Publication number	Publication date
ZA766166B (en)	1978-05-30
HK3183A (en)	1983-01-20
IE43778B1 (en)	1981-05-20
FR2327764B1 (cs)	1979-03-02
BE847368A (fr)	1977-04-15
DK454176A (da)	1977-04-18
FR2327764A1 (fr)	1977-05-13
PT65719A (fr)	1976-11-01
NO144468C (no)	1981-09-09
AT362510B (de)	1981-05-25
DK146194C (da)	1984-01-02
DE2546577A1 (de)	1977-04-21
JPS5854122B2 (ja)	1983-12-02
AU508628B2 (en)	1980-03-27
DK146194B (da)	1983-07-25
IL50686A0 (en)	1976-12-31
CS199647B2 (en)	1980-07-31
GB1560406A (en)	1980-02-06
FI762875A7 (cs)	1977-04-18
PH14513A (en)	1981-08-24
NZ182341A (en)	1978-09-20
CH643737A5 (en)	1984-06-29
SE7611189L (sv)	1977-04-18
JPS5251014A (en)	1977-04-23
NO763446L (cs)	1977-04-19
CA1079641A (en)	1980-06-17
NL184558B (nl)	1989-04-03
IE43778L (en)	1977-04-17
HU172533B (hu)	1978-09-28
IL50686A (en)	1979-05-31
NO144468B (no)	1981-06-01
GR61268B (en)	1978-10-17
SG63082G (en)	1983-09-09
NL7611295A (nl)	1977-04-19
DE2546577B2 (de)	1981-04-02
PT65719B (fr)	1978-06-12
MY8400063A (en)	1984-12-31
SE430379B (sv)	1983-11-14
AU1875476A (en)	1978-04-20
NL184558C (nl)	1989-09-01
ATA767976A (de)	1980-10-15
ES452420A1 (es)	1978-04-16

Publication	Publication Date	Title
SU1165223A3 (ru)	1985-06-30	Способ получени эргоалкалоидов
KR950006710B1 (ko)	1995-06-21	암로디핀의 베실레이트염의 제조방법
KR100664560B1 (ko)	2007-01-03	Ｌ(-)-카르니틴의 비흡습성 염을 제조하는 신규한 방법
US8796451B2 (en)	2014-08-05	Crystalline pharmaceutical
GB2062467A (en)	1981-05-28	Aqueous solution of nitroglycerin
AU7723894A (en)	1995-04-03	Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
NZ242191A (en)	1994-07-26	Crystalline tiagabine hydrochloride monohydrate, preparation and pharmaceutical compositions thereof
CN111406056A (zh)	2020-07-10	4-(4-(1-异丙基-7-氧代-1,4,6,7-四氢螺[吲唑-5,4’-哌啶]-1’-羰基)-6-甲氧基吡啶-2-基)苯甲酸的结晶2-氨基-2-(羟甲基)丙烷-1,3-二醇盐
FI70138C (fi)	1986-09-15	Foerfarande foer framstaellning av en foerbaettrad injekterbarloesning innehaollande kalcium/magnesium/oxitetracyklinsa mklat
CN118598799A (zh)	2024-09-06	一种门冬氨酸左旋氨氯地平原料药、片剂及制备方法
AU2001250920B2 (en)	2006-06-29	Crystalline pharmaceutical
AU2001250920A1 (en)	2002-01-03	Crystalline pharmaceutical
SU1053748A3 (ru)	1983-11-07	Способ получени тетрагидро 2 @ бензо-/ @ /-пиррола
EP1549616A1 (en)	2005-07-06	Organic acid salt of amlodipine
KR950007228B1 (ko)	1995-07-07	암로디핀의 베실레이트염
RU2042686C1 (ru)	1995-08-27	Кристаллический этопозид 4`-фосфат диэтанолсольват и способ его получения
SU648101A3 (ru)	1979-02-15	Способ получени стабильной полиморфной формы 1-окси-3-(1,1-диметилгептил)-6,6-диметил-6,6а,7,8,10,10агексагидро-9н-дибензо (в, ) пиран9-она
CN116947850A (zh)	2023-10-27	一种盐酸小檗碱与间羟基苯甲酸共晶及其制备方法
EP0012496A1 (en)	1980-06-25	A process for the preparation of a solid sodium amoxycillin and aqueous solutions thereof
KR19990014934A (ko)	1999-02-25	피롤리디닐 메틸 인돌의 염
CN121487928A (zh)	2026-02-06	(3r)-n-[2-氰基-4-氟-3-(3-甲基-4-氧代-喹唑啉-6-基)氧基-苯基]-3-氟-吡咯烷-1-磺酰胺的新固体形式
SU537070A1 (ru)	1976-11-30	Диметилбензосульфонат кускгигрина в качестве ганглиоблокатора кратковременного действи
EP2880040A1 (en)	2015-06-10	Bortezomib esters and formulations thereof
ZA200206962B (en)	2003-09-25	Crystalline pharmaceutical.
SI9011607A (sl)	1997-08-31	Postopek za pripravo čiste oblike polimorfne modifikacije b cimetidina in mešanic polimorfne modifikacije a cimetidina in polimorfne modifikacije b cimetidina v poljubnem razmerju komponent